KCNH2 and breast carcinoma: For example, the hERG activator, NS1643, has shown promise in inhibiting the growth of breast cancer cells, making it a potential candidate for cancer therapy (Fukushiro-Lopes, et al., 2018; Senyuk, et al., 2021).